Please login to the form below

Not currently logged in
Email:
Password:

mRNA technology

This page shows the latest mRNA technology news and features for those working in and with pharma, biotech and healthcare.

Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics

Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics

With the agreement, Pfizer’s access to LNP formulation technology will be significantly expanded, giving the company a strategic fit with its existing mRNA strategy. ... We are making significant investments to harness the power of the mRNA-LNP

Latest news

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • After the wildfire: how will healthcare recover from the pandemic? After the wildfire: how will healthcare recover from the pandemic?

    Some of the ‘early regrowth’ is also already familiar, with telemedicine, decentralised clinical trials and mRNA as a drug technology platform being prime examples. ... In particular, the idea that contact between health consumers and healthcare

  • Deal Watch March 2017 Deal Watch March 2017

    In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product ... 90. Arbutus Biopharma. Alexion. Licence. Lipid Nanoparticle (LNP)

  • Deal Watch June 2016 Deal Watch June 2016

    Back to the immuno-oncology theme, near the end of June Merck &Co signed a collaboration agreement with Moderna Therapeutics to use Moderna's mRNA technology to develop personalised cancer vaccines. ... The mRNA vaccines will also be assessed in

  • Deal Watch November 2015 Deal Watch November 2015

    Sanofi will gain access to BioNTech's mRNA formulation technology to generate new cancer immunotherapies. ... Dermatology focused R&D company with formulation technology and 3 clinical stage projects.

  • Pharma deals during March 2013 Pharma deals during March 2013

    In its $420m five-year alliance with Moderna Therapeutics, AZ is making an upfront payment of $240m for the discovery of messenger RNA (mRNA) therapeutics. ... 545. Moderna Therapeutics/ AstraZeneca. Development &commercialisation. mRNA technology for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... Governing board member of the European Institute

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...